Commercially Available Angiotensin II At2 Receptor Antibodies Are Nonspecific

Lack of Specificity of Commercial Antibodies Leads to Misidentification of Angiotensin Type-1 Receptor Protein

(2013) Katherine J. Elliott et al.   HYPERTENSION

Six Commercially Available Angiotensin II AT1 Receptor Antibodies are Non-specific

(2012) Julius Benicky et al.   CELLULAR AND MOLECULAR NEUROBIOLOGY

Angiotensin II AT1receptor blockers as treatments for inflammatory brain disorders

(2012) Juan M. Saavedra   CLINICAL SCIENCE

Angiotensin II type 2 receptor agonists – where should they be applied?

(2012) Ulrike Muscha Steckelings et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Angiotensin II type 2 receptor agonists: where should they be applied?

(2012) Koen Verdonk et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Lack of Specificity of Commercial Antibodies Leads to Misidentification of Angiotensin Type 1 Receptor Protein

(2012) Marcela Herrera et al.   HYPERTENSION

AT2 receptors: beneficial counter-regulatory role in cardiovascular and renal function

(2012) Shetal H. Padia et al.   PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY

Endothelial Cell–Specific Deficiency of Ang II Type 1a Receptors Attenuates Ang II–Induced Ascending Aortic Aneurysms in LDL Receptor −/− Mice

(2011) Debra L. Rateri et al.   CIRCULATION RESEARCH

Tissue Renin-Angiotensin-Aldosterone Systems: Targets for Pharmacological Therapy

(2010) Michael Bader   Annual Review of Pharmacology and Toxicology

The angiotensin AT2 receptor in inflammation

(2010) F. Rompe et al.   DRUG NEWS & PERSPECTIVES

Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications

(2010) Juan M. Saavedra et al.   PSYCHONEUROENDOCRINOLOGY

The potential role of the angiotensin subtype 2 receptor in cardiovascular protection

(2009) Helmy M. Siragy   CURRENT HYPERTENSION REPORTS

The angiotensin II type 2 (AT2) receptor: an enigmatic seven transmembrane receptor

(2009) Enzo et al.   Frontiers in Bioscience-Landmark

How reliable are G-protein-coupled receptor antibodies?

(2009) Martin C. Michel et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Lack of specificity of antibodies directed against human beta-adrenergic receptors

(2009) Nazha Hamdani et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Analyzing the validity of GalR1 and GalR2 antibodies using knockout mice

(2009) Xiaoying Lu et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Lack of specificity of commercially available antisera against muscarinergic and adrenergic receptors

(2009) Wisuit Pradidarcheep et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Seven decades of angiotensin (1939–2009)

(2009) Ranko Skrbic et al.   PEPTIDES

Increased Angiotensin II AT1 receptor mRNA and binding in spleen and lung of AT2 receptor gene disrupted mice

(2009) Jaroslav Pavel et al.   REGULATORY PEPTIDES

Angiotensin AT 2 Receptor Stimulation Causes Neuroprotection in a Conscious Rat Model of Stroke

(2009) Claudia A. McCarthy et al.   STROKE

A Guide to the Perplexed on the Specificity of Antibodies

(2008) Clifford B. Saper   JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY

Specificity of Immunoreactions: The Importance of Testing Specificity in Each Method

(2008) A. Lorincz et al.   JOURNAL OF NEUROSCIENCE

Suitability of muscarinic acetylcholine receptor antibodies for immunohistochemistry evaluated on tissue sections of receptor gene-deficient mice

(2008) Gitte Jositsch et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Ten commercial antibodies for alpha-1-adrenergic receptor subtypes are nonspecific

(2008) Brian C. Jensen et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Should we be cautious on the use of commercially available antibodies to dopamine receptors?

(2008) Serena Bodei et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY